James Love is joining Bill of Health as a regular contributor.
James Love is the Director of Knowledge Ecology International, where his research focuses on the production, management and access to knowledge resources, and aspects of competition policy. This includes work on the financing of R&D, intellectual property rights, prices for and access to new drugs, vaccines and other medical technologies, as well as related topics for other knowledge goods, including software, other copyrighted works, and data. He previously worked for the Center for Study of Responsive Law, and before that, as Senior Economist for the Frank Russell Company. He has a MPA from Harvard University’s Kennedy School of Government and an MA from Princeton’s Woodrow Wilson School of Public and International Affairs. James will be blogging about the policies to grant or revoke exclusive rights to make and sell medical products, as well as drug development costs.
- Delinkage Of R&D Costs From Product Prices, IP-Watch.Org, September 15, 2016.
- Discussion paper: An economic perspective on delinking the cost of R&D from the price of medicines, UNITAID. February 2016.
- Colombia Asked To Declare Excessive Price For Cancer Drug Contrary To Public Interest, Grounds For Compulsory License, Inside Views, IP-Watch.Org, December 3, 2015 (with Andrew S. Goldman).
- Drug Talking Drug Prices, Pt 4: Drug pricing is out of control, what should be done? PLOS Blogs. October 19, 2015.
- The TPP’s Reckless Proposals For Damages Will Have Negative Impact On Future Reform Of IPR Regimes, IP-Watch.Org July 28, 2015.
- TPP should protect patients, not patents, The Hill, June 12, 2015.
- TPP, designed to make medicine more expensive, reforms more difficult, Medium, June 8, 2015.